Joppe W. Hovius
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joppe W. Hovius has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Dieuwertje Hoornstra
Department of Internal Medicine, Division of Infectious Diseases & Center for Experimental and Molecular Medicine, Amsterdam UMC, Amsterdam 1105 AZ, Netherlands
3 shared publications Marina I. Sokolova
Central Research Institute of Epidemiology, Moscow, Russia
2 shared publicationsA. Wagemakers
Amsterdam UMC, Center for Experimental and Molecular Medicine, Amsterdam Institute of Infection and Immunology, University of Amsterdam, Amsterdam, The Netherlands
1 shared publicationAgnetha Hofhuis
Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands
1 shared publicationAlex Wagemakers
Center for Experimental and Molecular Medicine, Academic Medical Center, Amsterdam University Medical Centers, Amsterdam, Netherlands
1 shared publicationAlexander E Platonov
Central Research Institute of Epidemiology, Moscow, Russia
1 shared publication
Latest Publications
- Open Access
- 23 October 2024
- Published by Elsevier in Journal of Infection
- Vol. 89 (6) , 106326
Exposure, infection and disease with the tick-borne pathogen Borrelia miyamotoi in the Netherlands and Sweden, 2007-2019
- 23 October 2024
- Published by Elsevier in Journal of Infection
- Vol. 89 (6) , 106326
Open AccessExposure, infection and disease with the tick-borne pathogen Borrelia miyamotoi in the Netherlands and Sweden, 2007-2019
- Open Access
- 21 December 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (6) , e0203622
Development and Validation of a Protein Array for Detection of Antibodies against the Tick-Borne Pathogen Borrelia miyamotoi
This paper describes the protein array as a novel serological test for the diagnosis ofBorrelia miyamotoidisease (BMD), by reporting the methodology, the development of a diagnostic algorithm, and its extensive validation. With rising numbers of ticks and tick bites, tick-borne diseases, such as BMD, urgently deserve further societal and medical attention.B. miyamotoiis prevalent inIxodesticks across the northern hemisphere.
- 21 December 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (6) , e0203622
Open AccessDevelopment and Validation of a Protein Array for Detection of Antibodies against the Tick-Borne Pathogen Borrelia miyamotoi
This paper describes the protein array as a novel serological test for the diagnosis ofBorrelia miyamotoidisease (BMD), by reporting the methodology, the development of a diagnostic algorithm, and its extensive validation. With rising numbers of ticks and tick bites, tick-borne diseases, such as BMD, urgently deserve further societal and medical attention.B. miyamotoiis prevalent inIxodesticks across the northern hemisphere.
- Open Access
- 13 September 2022
- Published by Elsevier in The Lancet Microbe
- Vol. 3 (10) , e772-e786
Prevalence and clinical manifestation of Borrelia miyamotoi in Ixodes ticks and humans in the northern hemisphere: a systematic review and meta-analysis
- 13 September 2022
- Published by Elsevier in The Lancet Microbe
- Vol. 3 (10) , e772-e786
Open AccessPrevalence and clinical manifestation of Borrelia miyamotoi in Ixodes ticks and humans in the northern hemisphere: a systematic review and meta-analysis
- Open Access
- 29 May 2021
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 21 (1) , 1-8
Ticking on Pandora’s box: a prospective case-control study into ‘other’ tick-borne diseases
Background: Tick-borne pathogens other than Borrelia burgdorferi sensu lato – the causative agent of Lyme borreliosis – are common in Ixodes ricinus ticks. How often these pathogens cause human disease is unknown. In addition, diagnostic tools to identify such diseases are lacking or reserved to research laboratories. To elucidate their prevalence and disease burden, the study ‘Ticking on Pandora’s Box’ has been initiated, a collaborative effort between Amsterdam University Medical Center and the National Institute for Public Health and the Environment. Methods: The study investigates how often the tick-borne pathogens Anaplasma phagocytophilum, Babesia species, Borrelia miyamotoi, Neoehrlichia mikurensis, spotted fever group Rickettsia species and/or tick-borne encephalitis virus cause an acute febrile illness after tick-bite. We aim to determine the impact and severity of these tick-borne diseases in the Netherlands by measuring their prevalence and describing their clinical picture and course of disease. The study is designed as a prospective case-control study. We aim to include 150 cases – individuals clinically suspected of a tick-borne disease – and 3 matched healthy control groups of 200 persons each. The controls consist respectively of a group of individuals with either a tick-bite without complaints, the general population and of healthy blood donors. During a one-year follow-up we will acquire blood, urine and skin biopsy samples and ticks at baseline, 4 and 12 weeks. Additionally, participants answer modified versions of validated questionnaires to assess self-reported symptoms, among which the SF-36, on a 3 monthly basis. Discussion: This article describes the background and design of the study protocol of ‘Ticking on Pandora’s Box’. With our study we hope to provide insight into the prevalence, clinical presentation and disease burden of the tick-borne diseases anaplasmosis, babesiosis, B. miyamotoi disease, neoehrlichiosis, rickettsiosis and tick-borne encephalitis and to assist in test development as well as provide recommendations for national guidelines. Trial registration: NL9258 (retrospectively registered at Netherlands Trial Register, trialregister.nl in in February 2021).
- 29 May 2021
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 21 (1) , 1-8
Open AccessTicking on Pandora’s box: a prospective case-control study into ‘other’ tick-borne diseases
Background: Tick-borne pathogens other than Borrelia burgdorferi sensu lato – the causative agent of Lyme borreliosis – are common in Ixodes ricinus ticks. How often these pathogens cause human disease is unknown. In addition, diagnostic tools to identify such diseases are lacking or reserved to research laboratories. To elucidate their prevalence and disease burden, the study ‘Ticking on Pandora’s Box’ has been initiated, a collaborative effort between Amsterdam University Medical Center and the National Institute for Public Health and the Environment. Methods: The study investigates how often the tick-borne pathogens Anaplasma phagocytophilum, Babesia species, Borrelia miyamotoi, Neoehrlichia mikurensis, spotted fever group Rickettsia species and/or tick-borne encephalitis virus cause an acute febrile illness after tick-bite. We aim to determine the impact and severity of these tick-borne diseases in the Netherlands by measuring their prevalence and describing their clinical picture and course of disease. The study is designed as a prospective case-control study. We aim to include 150 cases – individuals clinically suspected of a tick-borne disease – and 3 matched healthy control groups of 200 persons each. The controls consist respectively of a group of individuals with either a tick-bite without complaints, the general population and of healthy blood donors. During a one-year follow-up we will acquire blood, urine and skin biopsy samples and ticks at baseline, 4 and 12 weeks. Additionally, participants answer modified versions of validated questionnaires to assess self-reported symptoms, among which the SF-36, on a 3 monthly basis. Discussion: This article describes the background and design of the study protocol of ‘Ticking on Pandora’s Box’. With our study we hope to provide insight into the prevalence, clinical presentation and disease burden of the tick-borne diseases anaplasmosis, babesiosis, B. miyamotoi disease, neoehrlichiosis, rickettsiosis and tick-borne encephalitis and to assist in test development as well as provide recommendations for national guidelines. Trial registration: NL9258 (retrospectively registered at Netherlands Trial Register, trialregister.nl in in February 2021).